{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"88.8","upperLimit":"94.1","value":"91.45"},{"groupId":"OG001","lowerLimit":"82.4","upperLimit":"89.1","value":"85.78"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"519"},{"groupId":"OG001","value":"512"}],"units":"Participants"}],"description":"Disease Free Probability where DFS time is defined as time from randomization end of induction to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free.","dispersionType":"95% Confidence Interval","groups":[{"description":"Capizzi Methotrexate (Combined)","id":"OG000","title":"ARM I and ARM II (Combination Chemotherapy)"},{"description":"High-Dose Methotrexate (Combined)","id":"OG001","title":"ARM III and ARM IV (Combination Chemotherapy)"}],"paramType":"NUMBER","populationDescription":"Includes subjects randomized to Capizzi Methotrexate versus High-Dose Methotrexate","reportingStatus":"POSTED","timeFrame":"4 years from randomization at the end of induction","title":"Disease-free Survival (DFS) for Randomized Methotrexate T-ALL Cohort (Arm I + Arm II vs. Arm III + Arm IV)","type":"PRIMARY","unitOfMeasure":"percent probability"}